Merck & Co., Inc. (MRK)
98.78
+1.16
(+1.19%)
USD |
NYSE |
Dec 11, 13:44
Merck Cash from Investing (Quarterly): -283.00M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -414.00M |
| Biogen, Inc. | -35.10M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Cidara Therapeutics, Inc. | -176.47M |
| Moderna, Inc. | 700.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 7.822B |
| Cash from Financing (Quarterly) | 2.638B |
| Free Cash Flow | 13.05B |
| Free Cash Flow Per Share (Quarterly) | 2.736 |
| Free Cash Flow to Equity (Quarterly) | 863.00M |
| Free Cash Flow to Firm (Quarterly) | 7.116B |
| Free Cash Flow Yield | 5.24% |